Warren Rose, assistant professor (CHS) in the Pharmacy Practice Division, received funding to further his research on staphylococcus aureus (S. aureas) biofilms and the barriers to antimicrobial therapy.

S. aureas is an epidemic pathogen in most hospital settings and is largely responsible for the most common type of hospital-based, device-related infection. The award from Astellas Pharma Inc. will support the study and evaluation of telavancin at multiple concentrations against staphylococcal biofilms, including MRSA in vitro.